Safety and efficacy of elagolix (with and without add-back therapy) for the treatment of heavy menstrual bleeding associated with uterine leiomyomas: a systematic review and meta-analysis

HIGHLIGHTS

• who: Mustafa Ali from the w Medical College, Dow University of Health Sciences, Karachi, Pakistan have published the research work: Safety and efficacy of elagolix (with and without add-back therapy) for the treatment of heavy menstrual bleeding associated with uterine leiomyomas: a systematic review and meta-analysis, in the Journal: (JOURNAL)
• what: The primary focus of this study would be to undertake a careful analysis of all evidence available, both new and old, to reach a consensus as to the role of elagolix with and without add-back therapy in reducing heavy menstrual bleeding . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.